Connor, Clark & Lunn Investment Management (CC&L)’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.87M Sell
46,429
-108,351
-70% -$14.3M 0.01% 676
2026
Q1
$21.6M Buy
154,780
+152,432
+6,492% +$21.3M 0.05% 308
2025
Q4
$288K Sell
2,348
-14,234
-86% -$1.73M ﹤0.01% 1396
2025
Q3
$1.84M Buy
16,582
+10,513
+173% +$1.19M 0.01% 878
2025
Q2
$673K Sell
6,069
-205,706
-97% -$21.9M ﹤0.01% 1168
2025
Q1
$23.7M Buy
211,775
+27,172
+15% +$2.8M 0.1% 162
2024
Q4
$17.1M Buy
184,603
+142,089
+334% +$12.8M 0.08% 200
2024
Q3
$3.56M Sell
42,514
-929,649
-96% -$70.9M 0.02% 524
2024
Q2
$66.7M Buy
972,163
+196,672
+25% +$13.1M 0.28% 83
2024
Q1
$56.8M Buy
775,491
+689,570
+803% +$53M 0.24% 89
2023
Q4
$6.96M Buy
85,921
+38,837
+82% +$3.02M 0.03% 345
2023
Q3
$3.53M Buy
47,084
+19,436
+70% +$1.49M 0.02% 480
2023
Q2
$2.13M Sell
27,648
-153,844
-85% -$12.3M 0.01% 598
2023
Q1
$15.1M Buy
181,492
+135,982
+299% +$11.3M 0.08% 188
2022
Q4
$3.91M Buy
45,510
+4,166
+10% +$330K 0.02% 400
2022
Q3
$2.55M Buy
41,344
+12,849
+45% +$810K 0.02% 444
2022
Q2
$1.76M Sell
28,495
-335,610
-92% -$20.8M 0.01% 497
2022
Q1
$21.6M Buy
364,105
+217,083
+148% +$13.9M 0.11% 148
2021
Q4
$10.7M Buy
147,022
+80,182
+120% +$5.52M 0.05% 233
2021
Q3
$4.67M Sell
66,840
-6,916
-9% -$486K 0.02% 352
2021
Q2
$5.08M Buy
73,756
+5,370
+8% +$359K 0.03% 356
2021
Q1
$4.42M Sell
68,386
-14,813
-18% -$955K 0.02% 387
2020
Q4
$4.85M Buy
83,199
+35,480
+74% +$2.14M 0.03% 344
2020
Q3
$3.02M Sell
47,719
-30,553
-39% -$2.12M 0.02% 401
2020
Q2
$6.02M Buy
78,272
+23,010
+42% +$1.76M 0.04% 267
2020
Q1
$4.13M Sell
55,262
-3,495
-6% -$241K 0.04% 285
2019
Q4
$3.82M Buy
58,757
+1,750
+3% +$114K 0.03% 315
2019
Q3
$3.61M Sell
57,007
-15,300
-21% -$1M 0.02% 312
2019
Q2
$4.88M Sell
72,307
-31,950
-31% -$2.1M 0.03% 290
2019
Q1
$6.78M Buy
104,257
+44,625
+75% +$2.97M 0.04% 237
2018
Q4
$3.73M Sell
59,632
-44,743
-43% -$3.13M 0.03% 316
2018
Q3
$8.06M Buy
104,375
+39,075
+60% +$2.95M 0.05% 243
2018
Q2
$4.63M Sell
65,300
-350
-0.5% -$24.7K 0.03% 321
2018
Q1
$4.95M Sell
65,650
-100,383
-60% -$7.98M 0.03% 278
2017
Q4
$11.9M Buy
166,033
+16,258
+11% +$1.23M 0.07% 186
2017
Q3
$12.1M Sell
149,775
-63,150
-30% -$4.83M 0.07% 182
2017
Q2
$15.1M Buy
212,925
+149,125
+234% +$9.92M 0.1% 143
2017
Q1
$4.33M Sell
63,800
-100
-0.2% -$7.03K 0.03% 270
2016
Q4
$4.58M Buy
63,900
+400
+0.6% +$29.7K 0.03% 262
2016
Q3
$5.02M Sell
63,500
-198,850
-76% -$16.2M 0.04% 245
2016
Q2
$21.9M Sell
262,350
-64,725
-20% -$5.74M 0.16% 110
2016
Q1
$30M Sell
327,075
-127,200
-28% -$11.5M 0.23% 72
2015
Q4
$46M Sell
454,275
-146,200
-24% -$15.2M 0.38% 44
2015
Q3
$59M Buy
600,475
+308,325
+106% +$34.2M 0.48% 43
2015
Q2
$34.2M Buy
+292,150
New +$31.9M 0.31% 55
2014
Q4
Sell
-161,700
Closed -$17.2M 604
2014
Q3
$17.2M Sell
161,700
-128,600
-44% -$12.6M 0.14% 76
2014
Q2
$25.6M Buy
+290,300
New +$22.6M 0.18% 73
2014
Q1
Sell
-258,173
Closed -$20.6M 708
2013
Q4
$20.6M Buy
258,173
+170,743
+195% +$11.9M 0.16% 69
2013
Q3
$5.65M Sell
87,430
-17,800
-17% -$1.06M 0.05% 102
2013
Q2
$5.69M Buy
+105,230
New +$5.48M 0.05% 96

Other funds holding GILD

Connor, Clark & Lunn Investment Management (CC&L)'s GILD Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Gilead Sciences (GILD) stake by 70% in Q2 2026, selling an estimated $14.3M and leaving 46,429 shares worth $5.87M. The position accounts for 0.01% of the portfolio, ranked #676.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $66.7M in Q2 2024. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 46,429 shares of Gilead Sciences worth $5.87M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 108,351 Gilead Sciences shares in Q2 2026, an estimated $14.3M.
  • Gilead Sciences made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #676 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Gilead Sciences position peaked at $66.7M in Q2 2024.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.